CHOICE: CHanges to Treatment and Outcomes in Patients With Type 2 Diabetes Initiating InjeCtablE Therapy

CompletedOBSERVATIONAL
Enrollment

2,515

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

exenatide

subcutaneous injection, 5mcg or 10mcg, twice a day

DRUG

any human insulin or analog insulin(s) given in any regimen by subcutaneous injection

Trial Locations (96)

Unknown

Research Site, Amager

Research Site, Rønne

Research Site, Toul

Research Site, Alsfeld

Research, Aschaffenburg

Research Site, Augsburg

Research Site, Aßlar

Research Site, Bad Aibling

Research Site, Bad Homburg

Research Site, Bad Mergentheim

Research Site, Bergheim

Research Site, Berlin

Research, Birkenfeld

Research Site, Bosenheim

Research Site, Bruchsal

Research Site, Dortmund

Research Site, Dresden

Research Site, Duisburg

Research Site, Eberswalde

Research Site, Eilenburg

Research Site, Eisenach

Research Site, Erfurt

Research Site, Essen

Research Site, Frankfurt

Research Site, Gebhardshain

Research Site, Gersfeld

Research Site, Giessen

Research Site, Gifhorn

Research Site, Grassau

Research Site, Groß-Gerau

Research Site, Hadmersleben

Research Site, Halle

Research Site, Hamburg

Research Site, Hammelburg

Research Site, Hennigsdorf

Research Site, Hohenmölsen

Research Site, Ismaning

Research Site, Köthen

Research Site, Kutenholz

Research Site, Langen

Research Site, Langenfeld

Research Site, Leipzig

Research Site, Lichtenfels

Research Site, Ludwigsburg

Research Site, Lüneburg

Research Site, Marburg

Research Site, Mayen

Research Site, Meissen

Research Site, Minden

Research Site, Mönchengladbach

Research Site, München

Research Site, Münster

Research Site, Nassau

Research Site, Netphen

Research Site, Oberhausen

Research Site, Pirmasens

Research Site, Recklinghausen

Research Site, Rehburg-Loccum

Research Site, Reichenbach

Research Site, Riesa

Research Site, Saarbrücken

Research Site, Saarlouis

Research Site, Schkeuditz

Research Site, Schönwalde

Research Site, Schweinfurt

Research Site, Seligenstadt

Research Site, Siegen

Research Site, Stockach

Research Site, Thale

Research Site, Ueckermünde

Research Site, Übach-Palenberg

Research Site, Villingen-Schwenningen

Research Site, Völklingen

Research Site, Warburg

Research Site, Weißenberg

Research Site, Werl

Research Site, Westfalica

Research Site, Wilhelmshaven

Research Site, Wurzen

Research Site, Kozani

Research Site, N. Efkarpia

Research Site, Thessaloniki

Research Site, Véroia

Research Site, Angered

Research Site, Ängelholm

Research Site, Dalby

Research Site, Falun

Research Site, Gothenburg

Research Site, Limhamn

Research Site, Luleå

Research Site, Malmo

Research Site, Skivarp

Research Site, Skövde

Research Site, Stockholm

Research Site, Vadstena

Research Site, Västervik

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

AstraZeneca

INDUSTRY